Private Capital Management (Minnesota)’s VanEck Biotech ETF BBH Stock Holding History

Private Capital Management (Minnesota)’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-1,000	Closed	-$126K	–	164
2017 Q2	$126K	Sell	1,000 -600	-38%	-$72.3K	0.14%	162
2017 Q1	$190K	Sell	1,600 -1,700	-52%	-$199K	0.21%	160
2016 Q4	$355K	Buy	3,300 +400	+14%	+$43.5K	0.4%	109
2016 Q3	$334K	Sell	2,900 -750	-21%	-$85.5K	0.35%	120
2016 Q2	$374K	Buy	3,650 +850	+30%	+$90.6K	0.37%	123
2016 Q1	$290K	Buy	2,800 +1,550	+124%	+$162K	0.27%	146
2015 Q4	$159K	Buy	+1,250	New	+$153K	0.15%	179

Other funds holding BBH

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

MCM

Murphy Capital Management Bedminster, New Jersey $720M AUM 9.22% 1-Year Est. Return

ECM

Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

SFS

Strategic Financial Services Utica, New York $2.28B AUM 22.9% 1-Year Est. Return

BRM

Boston Research & Management Manchester, Massachusetts $453M AUM 20.53% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Private Capital Management (Minnesota)'s BBH Position: Q3 2017 in Review

Private Capital Management (Minnesota) sold out of VanEck Biotech ETF (BBH) in Q3 2017, closing a stake of 1,000 shares — an estimated $126K sold.

Private Capital Management (Minnesota) first reported a position in BBH in Q4 2015 and held it in 7 quarters. The position peaked at $374K in Q2 2016. 79 funds tracked by Wall St. Rank hold BBH as of Q3 2017.

Private Capital Management (Minnesota) reported no remaining VanEck Biotech ETF position as of Q3 2017 after selling out during the quarter.
Private Capital Management (Minnesota) sold 1,000 VanEck Biotech ETF shares in Q3 2017, an estimated $126K.
Private Capital Management (Minnesota) first reported a position in VanEck Biotech ETF in Q4 2015 and held it in 7 quarters.
Private Capital Management (Minnesota)'s VanEck Biotech ETF position peaked at $374K in Q2 2016.
79 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q3 2017.

Based on Private Capital Management (Minnesota)'s 13F filing for Q3 2017, filed 26 Oct 2017.